Sorafenib with or without concurrent transarterial chemoembolization in hepatocellular carcinoma: a cautionary comment of STAH trial

Detalles Bibliográficos
Autores principales: Chen, Jia-Hao, Liu, Xu, Chen, Kang, Hu, Xiao-Yin, Xiang, Bang-De, Yuan, Wei-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797615/
https://www.ncbi.nlm.nih.gov/pubmed/35117195
http://dx.doi.org/10.21037/tcr.2019.12.51

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797615/
https://www.ncbi.nlm.nih.gov/pubmed/35117195
http://dx.doi.org/10.21037/tcr.2019.12.51

Ejemplares similares